Compare
AIM ImmunoTech Inc. vs Inmune Bio, Inc. vs Humacyte, Inc. vs TScan Therapeutics, Inc.
| Latest fiscal year | AIM ImmunoTech Inc. AIM | Inmune Bio, Inc. INMB | Humacyte, Inc. HUMA | TScan Therapeutics, Inc. TCRX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $88.0K | $50.0K | $2.04M | $10.32M |
| Revenue growth (YoY) | -48.2% | +257.1% | n/a | +266.7% |
| Gross margin | n/a | n/a | -376.1% (computed) | n/a |
| Operating margin | n/m | n/m | n/m | n/m |
| Net margin | n/m | n/m | n/m | n/m |
| Net income | -$13.96M | -$45.93M | -$40.83M | -$129.77M |
| EPS (Diluted) | -$8.62 | -$1.86 | -$0.26 | -$1.00 |
| Operating cash flow | -$10.96M | -$22.58M | -$105.04M | -$135.32M |
| Free cash flow | n/a | -$23.62M | -$105.93M | -$139.73M |
| Cash & equivalents | $2.98M | $24.75M | $50.50M | $152.41M |
| Total assets | $5.78M | $32.35M | $116.37M | $228.79M |
| Total liabilities | $15.56M | $8.83M | $113.26M | $105.67M |
| Shareholders' equity | -$9.78M | $23.52M | $3.11M | $123.12M |
| Return on year-end equity | n/a | -195.3% | n/m | -105.4% |
| Shares outstanding | 3.07M | 26.59M | 193.00M | n/a |
Revenue, most recent five fiscal years
| Fiscal year | AIM ImmunoTech Inc. | Inmune Bio, Inc. | Humacyte, Inc. | TScan Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | $88.0K Ended 2025-12-31 | $50.0K Ended 2025-12-31 | $2.04M Ended 2025-12-31 | $10.32M Ended 2025-12-31 |
| 1 year earlier | $170.0K Ended 2024-12-31 | $14.0K Ended 2024-12-31 | $0 Ended 2024-12-31 | $2.82M Ended 2024-12-31 |
| 2 years earlier | $202.0K Ended 2023-12-31 | $155.0K Ended 2023-12-31 | n/a | $21.05M Ended 2023-12-31 |
| 3 years earlier | $141.0K Ended 2022-12-31 | $374.0K Ended 2022-12-31 | n/a | $13.54M Ended 2022-12-31 |
| 4 years earlier | $135.0K Ended 2021-12-31 | $181.0K Ended 2021-12-31 | n/a | $10.14M Ended 2021-12-31 |